A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PMED)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02980068 |
|
Recruitment Status :
Recruiting
First Posted : December 2, 2016
Last Update Posted : May 10, 2018
|
Sponsor:
Gladwin, Mark, MD
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Alison Morris, University of Pittsburgh
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in healthy adult normal volunteers compared to volunteers with PH-HFpEF in the breakdown of oral nitrate.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary; Hypertension Heart Failure Preserved Ejection Fraction | Drug: Nitrates | Phase 1 |
We will enroll 60 Group II PH (PH-HFpEF) patients and 60 matched healthy controls over three years. The Subjects will receive a single dose of one of the two study drugs, determined by whether they will participate in one study visit or two: 15N nitrate (1,000 mg) or 14N Sodium Nitrate: standard sodium nitrate, and all will receive one dose of CLA 3g. Twenty of the Group II PH subjects and 20 of the control subjects willing to return for a follow up visit 24 hours after drug administration will receive 15N nitrate. All others will receive standard sodium nitrate. CLA will be obtained from GNC (General Nutrition Corporation) and given once.
Throughout the experiment, we will measure blood pressure, heart rate, and respiratory rate as well as co-oximetry. Plasma samples are collected at approximate times 0, 2, and 6 hrs post-drug administration. Urine will be collected at approximate times 0 and 6 hrs. We will examine plasma and urine nitrate and nitrite. The 40 subjects who return for a second visit 24 hours post-drug administration will provide an additional plasma and urine sample.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open Label Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults |
| Actual Study Start Date : | August 28, 2017 |
| Estimated Primary Completion Date : | July 2020 |
| Estimated Study Completion Date : | July 2021 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Sodium nitrate
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 15N Nitrate
single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
|
Drug: Nitrates
1,000 mg/11.8 mmol, oral, on day one, hour zero
Other Name: 15N Nitrate |
|
Experimental: 14N Sodium Nitrate
single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
|
Drug: Nitrates
1,000 mg/11.18 mmol, oral, on day hour, hour zero
Other Name: 14N Sodium Nitrate |
Primary Outcome Measures :
- Change in nitrate level in urine [ Time Frame: Urine collected approx 0 & 6 hours after drug administration ]The investigators will examine urine nitrate
- Change in nitrate level in plasma [ Time Frame: Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration ]The investigators will examine plasma nitrate
- Bacterial content of gut microbiome [ Time Frame: Stool collected at conclusion of study visit or up to 48 hours after drug administration ]Stool will be analyzed for bacterial makeup
- Bacterial content of the oral microbiome [ Time Frame: Tongue scraping will occur immediately preceding administration of drug ]Tongue scraping will be analyzed for bacterial makeup
- Change in nitrite level in urine [ Time Frame: Urine collected approx 0 & 6 hours after drug administration ]The investigators will examine urine nitrite
- Change in nitrite level in plasma [ Time Frame: Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration ]The investigators will examine plasma nitrite
Secondary Outcome Measures :
- Change in blood pressure [ Time Frame: Frequently over 6 hour study visit ]
- Change in heart rate [ Time Frame: Continuous over 6 hour study visit ]
- Change in respiratory rate [ Time Frame: Continuous over 6 hour study visit ]
- Change in hemoglobin concentration [ Time Frame: Continuous over 6 hour study visit ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Undergoing clinical right heart catheterization or RHC in the past 6 months.
- PH-HFpEF group: PH secondary to heart failure with preserved ejection fraction (PH-HFpEF) hemodynamically defined by a mean PAP ≥ 25 mm Hg, a PCWP > 15 mm Hg, and have a PVR > 3 Woods units and normal cardiac index (>2.0 L/min/m2)
- Control group: Normal hemodynamics (mean PAP < 25 mm Hg, PCWP ≤ 15 mm Hg) on clinical right heart catheterization within the prior 6 months
- Ability to provide written informed consent
Exclusion Criteria:
- Use of systemic antibiotics, chlorhexidine mouthwash, or immune-suppression (oral prednisone, chemotherapy, etc.) within the previous three months
- Use of a phosphodiesterase-5 inhibitor (PDE-5i) within 7 days of drug administration
- Current pregnancy or lactation
- Uncontrolled systemic hypertension based on repeated measurement of sitting systolic blood pressure >185 mm Hg or sitting diastolic blood pressure >110 mm Hg at screening
- History of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as moderate to severe hepatic impairment (Child-Pugh Class B-C)
- Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at screening or requires dialytic support
- Known history of left ventricular ejection fraction < 45% by multiple gated acquisition scan (MUGA), angiography, or echocardiography
- History of atrial septostomy
- Repaired or unrepaired congenital heart disease
- Pericardial constriction
- Restrictive or congestive cardiomyopathy
- Symptomatic coronary disease with demonstrable ischemia
- Addition or change in dosing of hormonal contraception medications (OCP, IUD, Depo-Provera) in the past 4 weeks
- Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study
- Active participation in other research studies with investigational drugs
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02980068
Contacts
| Contact: Cathy Kessinger, RN | 412-624-8330 | kessingercj@pitt.edu | |
| Contact: Cathy Kessinger, RN | 412-624-8330 | kessingercj@upmc.edu |
Locations
| United States, Pennsylvania | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Noel Britton, MPH 412-383-5289 brittonm@upmc.edu | |
| Contact: Cathy Kessinger, RN 412-624-8330 kessingercj@upmc.edu | |
| Principal Investigator: Alison Morris, MD, MS | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Alison Morris, MD 412-624-8330 morrisa@upmc.edu | |
| Contact: Cathy kessingercj, RN 4126248330 kessingercj@upmc.edu | |
Sponsors and Collaborators
Gladwin, Mark, MD
National Heart, Lung, and Blood Institute (NHLBI)
| Responsible Party: | Alison Morris, Professor, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT02980068 History of Changes |
| Other Study ID Numbers: |
PRO16090149 5P01HL103455 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 2, 2016 Key Record Dates |
| Last Update Posted: | May 10, 2018 |
| Last Verified: | October 2017 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Additional relevant MeSH terms:
|
Hypertension Heart Failure Hypertension, Pulmonary Vascular Diseases |
Cardiovascular Diseases Heart Diseases Lung Diseases Respiratory Tract Diseases |